Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer

Study summary

The purpose of this study is to see if this combination of chemotherapy plus radiation therapy and immunotherapy (with bevacizumab) expands treatment options for patients with non-small cell lung cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedBevacizumab and Pemetrexed

Plus 4 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 9, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?SCRI Development Innovations, LLC

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: SCRI Development Innovations, LLC
Interventions being studied: Drug: Bevacizumab; Drug: Pemetrexed; Procedure: Radiotherapy; Other: Folic Acid; Other: vitamin B12; Drug: carboplatin

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Early-stage or resectable→Locally advanced→

Treatment approach

Immunotherapy→Chemotherapy→Radiation therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Clinically confirmed non-small cell lung cancer stage IIIA and selected stage IIIB
Measurable or evaluable disease
Be up and about and able to care for self
Adequate kidney, liver and bone marrow function
No prior treatment for this disease
Must be able to give written informed consent
Must be able to take folic acid, vitamin B12 and dexamethasone as described in the protocol
Age 18 years or older

Reasons someone may not be able to joinExclusion criteria

Stage IV or IIIB patients with pleural or pericardial effusions
Stage IIIB disease with contralateral mediastinal nodes greater than 4cm
Squamous cell predominant tumors
Pregnant or lactating women
Patients with active infections
History of another cancer within the last 5 years with the exception of skin cancer or cervical carcinoma in situ
History of stroke, transient ischemic attacks, or acute MI within the past 6 months or any other serious cardiovascular disease
Symptoms of peripheral vascular disease
History of neurological disease
Recent history of blood in the sputum or vomitus
Non-healing wounds, ulcer or long bone fractures
History of bleeding problems or coagulation problems
History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 6 months
History of uncontrolled hypertension
Chronic use of non-steroidal anti-inflammatory medication not allowed on this study Please note: There are additional inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Gainsville Hematology Oncology AssociatesGainesville, Florida
Watson Clinic Center for Cancer Care and ResearchLakeland, Florida
Wellstar Cancer ResearchMarietta, Georgia
Consultants in Blood Disorders and CancerLouisville, Kentucky
Oncology Hematology CareCincinnati, Ohio
Associates in Hematology OncologyChattanooga, Tennessee
Tennessee Oncology, PLLCNashville, Tennessee

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 9, 2021. Always confirm current availability with the study team.

View original record ↗